Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Pengfei Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2152-8165; OpenAlex author ID A5101606280. Sources: OpenAlex.

Their work

Papers
19
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 19

  1. Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics. Co-author DOI 10.1136/gutjnl-2025-335683↗
  2. Ferroptosis in cancer toward molecular insights and clinical translation in pancreatic cancer. Co-author DOI 10.1186/s12943-025-02567-5↗
  3. Peptidase inhibitor 16 promotes proliferation of pancreatic ductal adenocarcinoma cells through OASL signaling. Co-author DOI 10.1002/mc.23699↗
  4. [Short-term outcomes of the TRIANGLE operation after neoadjuvant chemotherapy in locally advanced pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20230615-000234↗
  5. Cost-effectiveness of open pancreaticoduodenectomy with or without Heidelberg TRIANGLE operation for pancreatic cancer in China. Co-author DOI 10.1007/s00432-023-05406-6↗
  6. Correction: CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing. Co-author DOI 10.1186/s12943-022-01636-3↗
  7. Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star. Co-author DOI 10.1186/s13578-022-00833-3↗
  8. Prognostic impact of the ratio of preoperative CA19-9 to liver enzyme levels in pancreatic cancer patients with jaundice (predictability of combined CA19-9/AST… Co-author DOI 10.1016/j.pan.2021.05.300↗
  9. DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer. Co-author DOI 10.1155/2021/6530298↗
  10. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.800268↗
  11. Prognostic Nomogram for Resected Pancreatic Adenocarcinoma: A TRIPOD-Compliant Retrospective Long-Term Survival Analysis. Co-author DOI 10.1007/s00268-019-05325-z↗
  12. [Comparison of radical antegrade modular pancreatosplenectomy with conventional distal pancreatectomy for pancreatic adenocarcinoma of the body and tail]. Co-author DOI 10.3760/cma.j.cn112139-20200413-00301↗
  13. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. Co-author DOI 10.1016/j.prp.2019.152666↗
  14. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway. Co-author DOI 10.1002/ijc.31173↗
  15. ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15-AS1 Methylation. Co-author DOI 10.1159/000491915↗
  16. Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regul… Co-author DOI 10.1186/s12943-018-0761-9↗
  17. Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis. Co-author DOI 10.1016/j.canlet.2017.03.024↗
  18. A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.22861↗
  19. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer. Co-author DOI 10.3760/cma.j.issn.0366-6999.20130748↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 16 shared papers, 2013–2026 · strength 1.96
  2. Yi Miao · 11 shared papers, 2017–2024 · strength 1.10
  3. Zipeng Lu · 11 shared papers, 2013–2022 · strength 0.96
  4. Qun Chen · 5 shared papers, 2021–2024 · strength 0.76
  5. Baobao Cai · 8 shared papers, 2013–2022 · strength 0.75
  6. Hao Yuan · 7 shared papers, 2017–2022 · strength 0.66
  7. Guodong Shi · 6 shared papers, 2017–2021 · strength 0.51
  8. Taoyue Yang · 3 shared papers, 2021–2022 · strength 0.39
  9. Peng Shen · 3 shared papers, 2021–2022 · strength 0.39
  10. Yang Feng Wu · 4 shared papers, 2017–2024 · strength 0.37
  11. Xumin Huang · 3 shared papers, 2020–2022 · strength 0.36
  12. Kai Zhang · 2 shared papers, 2021–2024 · strength 0.31
  13. Qun Chen · 1 shared paper, 2026 · strength 0.30
  14. Jiangtao Yin · 2 shared papers, 2020–2024 · strength 0.28
  15. Jishu Wei · 2 shared papers, 2020–2024 · strength 0.28
  16. Yi Miao · 3 shared papers, 2013–2022 · strength 0.26
  17. Robert A. Anders · 1 shared paper, 2026 · strength 0.26
  18. Yongsu Ma · 1 shared paper, 2026 · strength 0.26
  19. Kai Chen · 1 shared paper, 2026 · strength 0.26
  20. Heng‐Chung Kung · 1 shared paper, 2026 · strength 0.26
  21. Yinmo Yang · 1 shared paper, 2026 · strength 0.26
  22. Xiaodong Tian · 1 shared paper, 2026 · strength 0.26
  23. Jacquelyn W. Zimmerman · 1 shared paper, 2026 · strength 0.26
  24. Wanli Ge · 2 shared papers, 2021–2022 · strength 0.26
  25. Dongfang Liu · 3 shared papers, 2018 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.